Across the US, the prevalence of acute respiratory illness causing people to seek healthcare is high.

COVID-19 has Increased.

While the flu and RSV currently dominate the headlines, it is crucial to recognize that COVID-19 remains a significant presence in our communities. According to the CDC, COVID-19 activities have increased in many areas of the country.

InBios is a Leader in COVID-19 Diagnostics.

It’s been five years since the first case of COVID-19 was diagnosed in the US. Using our infectious disease expertise, InBios quickly developed a portfolio of COVID-19 diagnostics including one of the easiest rapid tests on the market.

*This product has not been FDA cleared or approved but has been authorized by FDA under an Emergency Use Authorization. This product has been authorized only for the detection of proteins from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated, or authorization is revoked sooner.

InBios International, Inc. | 206-344-5821 | inquiries@inbios.com | www.inbios.com

 InBios is GMP compliant, FDA registered, USDA licensed and is ISO 13485:2016 certified. 100% manufactured in the USA.